Following Wednesday s announcement that Google spin-off Calico and drug firm AbbVie will spend up to $1.5 billion on age-related treatments, Calico CEO Art Levinson is stepping down from another drug firm s board to avoid a conflict of interest.
Levinson said he ll resign as a director of Swiss giant Roche, which owns South San Francisco biotech company Genentech, where Levinson was CEO from 1995 to 2009.
In a press release, Roche Chairman Christoph Franz said, we regret Art s decision but at the same time understand his reasons.
Photo by Patrick Tehan, Mercury News
